HC Wainwright Issues Positive Forecast for Intensity Therapeutics (NASDAQ:INTS) Stock Price

Intensity Therapeutics (NASDAQ:INTS) had its price target boosted by investment analysts at HC Wainwright from $5.00 to $7.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 62.04% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Intensity Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Intensity Therapeutics Stock Up 4.1%

Shares of INTS traded up $0.17 during midday trading on Tuesday, hitting $4.32. 6,368 shares of the company’s stock traded hands, compared to its average volume of 43,093. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $14.08 million, a price-to-earnings ratio of -0.76 and a beta of 2.76. Intensity Therapeutics has a 1 year low of $3.51 and a 1 year high of $43.50. The firm’s fifty day moving average is $4.26 and its 200-day moving average is $5.48.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.24). As a group, sell-side analysts anticipate that Intensity Therapeutics will post -2.7 earnings per share for the current year.

Hedge Funds Weigh In On Intensity Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legacy Advisors LLC purchased a new stake in Intensity Therapeutics during the 4th quarter valued at about $63,000. Jane Street Group LLC purchased a new position in shares of Intensity Therapeutics in the fourth quarter worth about $26,000. Geode Capital Management LLC raised its stake in shares of Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares during the last quarter. State Street Corp lifted its holdings in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the period. Finally, Corient Private Wealth LLC acquired a new stake in shares of Intensity Therapeutics during the fourth quarter worth about $41,000. Hedge funds and other institutional investors own 3.74% of the company’s stock.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.